Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Frigeri
Ferdinando
F
Arcamone
Manuela
M
Luciano
Luigia
L
Di Francia
Raffaele
R
Pane
Fabrizio
F
Pinto
Antonio
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D000069439:Dasatinib; D016313:Genes, abl / Q000502:physiology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D013844:Thiazoles / Q000627:therapeutic use*; D017211:Treatment Failure
D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib